KDIGO is updating the KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases on an ongoing, chapter-by-chapter basis. The Kidney Disease: Improving Global Outcomes (KDIGO) 2023 Clinical Practice Guideline for Lupus Nephritis is now available for public review. We invite you to review this chapter update and share your candid comments and suggestions. Based on your input, we will prepare a final revised version for publication. We kindly request that you submit your feedback no later than Monday, March 27.
Please note that by agreeing to provide feedback on a KDIGO draft guideline document, you permit KDIGO to acknowledge your participation as a reviewer in the final publication.
The KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases was published in the October 2021 issue of Supplements to Kidney International with an Executive Summary in the main pages of the journal. This guideline is the most extensive in KDIGO history, organized into eleven chapters, ten of which cover a specific primary or secondary glomerular disease or group of diseases. The first chapter is an extensive review of general management principles that should be considered for patients with any type of glomerular disease. All topics will be reassessed on a continuous basis and will be updated based on the availability of new evidence that may alter a guideline statement in the previous version.
Brad Rovin, MD (United States), and Jürgen Floege, MD (Germany) co-chaired the guideline chapter update as well as the original Glomerular Diseases Guideline.
CLICK HERE to provide feedback on the KDIGO 2023 Lupus Nephritis Guideline.
CJASN
How I Treat: Focal Segmental Glomerulosclerosis (FSGS)
How I Treat: Steroid-Sensitive Nephrotic Syndrome in Children (SSNS)
How I Treat: Lupus Nephritis (LN)
How I Treat: Rituximab in the Frail and Elderly with Severe ANCA-Associated GN
How I Treat: IgA Nephropathy (IgAN)
KDIGO-Arkana 2022 Pathology Slide Set based on the KDIGO 2021 GD Guideline
Looking to the Future: Applying a Greater Understanding of Proteinuria Regulation to Improve Outcomes of Patients with FSGS and IgAN
DISCLAIMER: USE OF THE CLINICAL PRACTICE GUIDELINES
This Clinical Practice Guideline is based upon the best information available at the time of publication. The recommendations are designed to provide information and assist decision-making. They are not intended to define a standard of care, and should not be construed as one. Neither should they be interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every health care professional making use of this Guideline is responsible for evaluating the appropriateness of applying them in the setting of any particular clinical situation. The recommendations for research contained within this document are general and do not imply a specific protocol.
